Clinical Trial Update: Study of Lorlatinib in ROS1 Rearranged NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update of lorlatinib in ROS1-rearranged non-small cell lung cancer (NSCLC) is cited with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Nonsmall Cell Lung Cancer | Phase 2 | Status: UNKNOWN